|

Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

RECRUITINGSponsored by International Extranodal Lymphoma Study Group (IELSG)
Actively Recruiting
SponsorInternational Extranodal Lymphoma Study Group (IELSG)
Started2024-04-11
Est. completion2026-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations2 sites
View on ClinicalTrials.gov →

NCT05700149

Summary

International retrospective observational cohort study aimed to describe a molecular classification for NMZL.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

1. Male or female adults 18 years or older
2. Diagnosis of NMZL on lymph node histology after Jan 1st, 2000
3. Availability of tumor material from lymph node (either frozen or FFPE) collected when the patient was treatment naïve
4. Availability of the baseline and follow-up annotations

Exclusion Criteria:

1\. Nodal spread of a clinically occult extranodal MZL (this must have been ruled out by carefully evaluating the extranodal tissues draining to the involved lymph nodes by imaging or endoscopy)

Conditions2

CancerNodal Marginal Zone Lymphoma

Locations2 sites

Florida

1 site
University of Miami
Miami, Florida, 33136
Jennifer Chapman, MD

New York

1 site
Weill Cornell Medical
New York, New York, 10065
Giorgio Inghirami, MD

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.